Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Monarch Capital Management Inc.

Monarch Capital Management Inc. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 106.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,067 shares of the biopharmaceutical company's stock after purchasing an additional 549 shares during the quarter. Monarch Capital Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $760,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $127,489,000. Icon Wealth Advisors LLC raised its position in Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock valued at $79,874,000 after purchasing an additional 75,569 shares during the period. State Street Corp lifted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 57.7% in the 2nd quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company's stock valued at $171,629,000 after purchasing an additional 59,745 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.7 %

Regeneron Pharmaceuticals stock traded down $11.65 during mid-day trading on Friday, reaching $681.58. 1,107,622 shares of the company were exchanged, compared to its average volume of 678,713. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market cap of $74.90 billion, a P/E ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The business has a fifty day moving average of $738.60 and a 200 day moving average of $949.32. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price target on the stock. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Finally, Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.